Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism
A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 127 participants.
Also called NCT02721888
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 127 participants
- Sponsor
- Centre Hospitalier Universitaire Dijon
- Registry
-
NCT02721888
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- Not reported
- Countries
- France
- Registry status
- Terminated
Technical summary
Registry record NCT02721888. Allocation not applicable; no masking; primary purpose treatment. Start 2012-07-10 (actual); primary completion 2019-10-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism
- Acronym
- LIRA-NAFLD/LIP
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Liraglutide
- Intervention (Drug)
- MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
- Intervention (Biological)
- Blood sample
- Intervention (Other)
- Kinetic substudy (10 patients)
- Lead sponsor
- Centre Hospitalier Universitaire Dijon
Record details
- Record id
cardio:ct-nct02721888- Content hash
5be24d74b5d2758a46dba7ae1af7e5002fd4135f81960c3e7e200d77a4c580cf